PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.

Authors:
Lagace TA.

Journal:
Curr Opin Lipidol

Publication Year: 2014

DOI:
10.1097/MOL.0000000000000114

PMCID:
PMC4166010

PMID:
25110901

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Curr Opin Lipidol

Abbreviation: Curr Opin Lipidol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Biochemistry

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Angiopoietin-like 3 inhibition and the liver: less is more?
Oostveen RF; Hovingh GK; Stroes ESG. (2023) - Transparency Score: 3/6
Genetic variation in apolipoprotein A-V in hypertriglyceridemia.
Perera SD; Hegele RA. (2023) - Transparency Score: 3/6
The pathophysiology of excess plasma-free cholesterol.
Gillard BK; Rosales C; Gotto AM and 1 more (2023) - Transparency Score: 3/6
Characteristics of plaque lipid-associated macrophages and their possible roles in the pathogenesis…
Kim K; Park SE; Park JS and 1 more (2022) - Transparency Score: 3/6
Considerations for routinely testing for high lipoprotein(a).
Nurmohamed NS; Moriarty PM; Stroes ES. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest There are no conflicts of interest."

Evidence found in paper:

"T.A.L is supported by operating grants from the Canadian Institutes of Health Research (MOP 106462) and the Heart and Stroke Foundation of Canada, and in part by a Heart and Stroke Foundation of Canada New Investigator Award."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025